US-based CELLINK develops bioprinting technologies to 3D print human tissues for testing pharmaceutical and cosmetic products. They aim for providing ready-to-print or use models for researchers and healthcare providers to enable 3D cell culture, personalized medicine, and enhanced therapeutics.

The company’s patent pending bioink is a biomaterial innovation that enables human cells to grow and thrive such as they would in the natural human body environment. The disruptive technology is used to print tissues such as liver, cartilage, skin, and even fully functional cancer tumors that can then be used to develop new cancer treatments.

They are present in over 40 countries, such as US, UK, Germany, Australia, or Japan. Their most popular products are skin constructs, and drug screening models.

The Medical Futurist asked Ariel Kramer, Chief Communications Officer of CELLINK and her team about their story, the future of bioprinting and the regulatory environment.

 Read more…